InduPro raises $77M Series B as it doses first patient in Phase 1 lung cancer trial

Seattle- and Cambridge-based biotech InduPro raised $77 million in a Series B to advance its oncology protein-therapeutics pipeline and is dosing the first patient in a Phase 1 trial targeting lung cancer and other solid tumors.